Personalised disease monitoring in childhood AML

Dr Andrew Moore from the University of Queensland Diamantina Institute is researching methods to monitor responses to AML therapy.
Dr Andrew Moore from the University of Queensland Diamantina Institute is researching methods to monitor responses to AML therapy.

Recipient: Dr Andrew Moore
Institute: University of Queensland Diamantina Institute
Funding: $474,591 July 2014 to June 2019

Methods to monitor response to Acute myeloid leukaemia (AML) therapy

Acute myeloid leukaemia (AML) is an aggressive leukaemia with a very poor prognosis for relapsed patients.

This project focusses on the most common subtype of AML, which sadly has a low survival rate due to high-risk of relapse in patients who initially appear to be in remission following therapy, but actually have very low levels of persistent leukaemia.

This research will develop new ways of monitoring the response to therapy, detect impending relapse, and identify specific markers associated with relapse in AML patients.

The insights gained from this research will inform future studies aimed at developing new therapies to prevent relapse and to treat patients who are not cured by currently available treatments.